Jonathan Talamo, MD.

SHERBORN, Mass.—CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced that Jonathan Talamo, MD, has been appointed as its new chair of the board directors. Dr. Talamo has served as a board member for the company since 2020. An ophthalmic surgeon with over 25 years in clinical practice, Dr. Talamo is a leader in corneal disease, cataract, and refractive surgery. After 25 years in the clinic, he pivoted to executive roles in biomedicine and health care.

As chief medical officer of Ocular Therapeutix, Dr. Talamo helped usher the development of Dextenza for post-surgical inflammation and managed a pipeline of ophthalmologic therapeutics. In his subsequent role as chief medical officer and worldwide vice president of Clinical and Medical Affairs at Johnson & Johnson Vision, Dr. Talamo helped lead the integration of Abbott Medical Optics and the global launch of multiple ophthalmologic products.

“I am thrilled to work more closely with the CXLO Board as we develop the minimally-invasive EpiSmart cross-linking system to improve patient comfort and preserve vision,” said Dr. Talamo. “I look forward to collaborating with the CXLO team to improve safety and clinical outcomes for patients with keratoconus.”

“With a career spanning ophthalmic surgery to therapeutic development and industry leadership, Jon brings a wealth of experience to our board,” said Michael D. Webb, president and chief executive officer of CXL Ophthalmics. “We look forward to Jon’s leadership as CXLO strives to deliver safer and more accessible care globally to the millions of patients at risk of vision loss due to keratoconus.”